Key takeaways
- GHK is glycine–histidine–lysine; GHK-Cu is its copper(II) complex.
- The GHK study summarized here used cultured human keratinocytes and a skin-equivalent model, not human participants.
- A 2006 randomized study of a GHK-Cu-containing skincare regimen had 13 completers; material sold online is not the formulation tested.
- FDA’s 503A list has an entry for GHK-Cu, for certain routes only, and none for GHK without copper; the Poisons Standard October 2026 names neither.
- Neither form is named on WADA’s 2026 or 2027 List; WADA says a peptide not specifically named “may still be prohibited”.
01GHK vs GHK-Cu in one table
This comparison separates the two chemical forms from what the cited study and status records establish. Regulatory findings are dated and scoped to the records checked.
| Question | GHK, copper-free | GHK-Cu |
|---|---|---|
| Identity | Glycine–histidine–lysine (GHK), a three-amino-acid peptide | GHK complexed with copper(II) |
| Evidence tier and model | T4: cultured human keratinocytes and a skin-equivalent model, in a 2012 laboratory study | T1, small: randomized human study of skincare regimens with or without GHK-Cu; 13 completed |
| Human-participant data in the studies cited here | The 2012 study used human cells and a skin-equivalent model, not human participants | 13 participants completed the 2006 randomized study; it assessed skin measures and questionnaires after laser resurfacing |
| United States, checked here | FDA’s 503A nominations list (updated 14 May 2026) has no entry for GHK without copper (searched 21 Nov 2026) | FDA’s 503A list places it in Category 1, “Bulk Drug Substances Under Evaluation”, for certain routes of administration only |
| United Kingdom, checked here | The emc medicines database returned no results for GHK (21 Nov 2026); it is not the full UK register | No results for GHK, copper tripeptide or prezatide in the same database (21 Nov 2026) |
| Australia, checked here | The TGA says “many products promoted online are unapproved therapeutic goods and may be unlawful to import, supply or advertise. Using unapproved peptide products can pose serious health risks.” GHK has no entry by name in the Poisons Standard October 2026; we draw no scheduling conclusion of our own | The TGA statement on the left applies to peptide products generally. GHK-Cu has no entry by name in the Poisons Standard October 2026, which has group entries for copper compounds; we draw no scheduling conclusion of our own |
| Sport, WADA 2026 and 2027 Lists | Not named. WADA says a peptide not specifically named “may still be prohibited” | Not named, as on the left |
02What changes when copper is present?
GHK names the three-amino-acid peptide: glycine, histidine, and lysine. GHK-Cu names a copper(II) complex of that peptide. The names are related, but the copper complex is a different chemical form. They should not be treated as interchangeable labels for interpreting a study or describing what a sample contains.
That chemical distinction is narrower than a claim about what either form does. The presence of copper tells you how the compounds differ by name; it does not, by itself, establish a difference in human outcomes, safety, or product quality. To make a performance comparison, research would need to compare the two forms under comparable conditions. The studies summarized on this page do not do that.
Three amino acids
The name refers to glycine, histidine, and lysine joined in one peptide.
Copper(II) complex
The added copper distinguishes this chemical form from copper-free GHK.
Separate study models
The studies summarized here do not directly compare the two forms.
03What did the cited studies measure?
GHK, copper-free. A 2012 laboratory study used cultured normal human keratinocytes and a skin-equivalent model. It assessed cell characteristics and markers in those models, and its authors concluded that copper-free GHK “showed similar effects with copper-GHK”; the abstract describes experiments with copper-free GHK and cites the group’s earlier copper-GHK work. This is T4 evidence: a human-cell model is not a study in human participants, and it is not evidence of an effect in people.
GHK-Cu. Miller and colleagues’ 2006 randomized study compared skincare regimens with or without GHK-Cu after carbon-dioxide laser resurfacing. Thirteen participants completed it. Researchers assessed redness over time, skin appearance, and questionnaire responses. On objective measures it found no statistically significant difference between groups: not in how soon redness resolved, and not in evaluators’ ratings of wrinkles or skin quality. This is a small human study, not a head-to-head test of copper-free GHK against GHK-Cu. Material sold online is not the formulation tested in that study.
If you searched “ghk basic vs ghk-cu,” the key distinction is chemical identity, not a ranking from these studies. “GHK basic” is not a name we found in PubMed (searched 21 November 2026) or in the regulator documents cited here; this page compares GHK without copper and GHK-Cu. For more context on study populations and limits, see our GHK-Cu research guide.
04What do the status records say?
United States. FDA’s 503A list, updated 14 May 2026, places GHK-Cu in Category 1, “Bulk Drug Substances Under Evaluation”, for certain routes of administration only, and FDA says it intends to consult its Pharmacy Compounding Advisory Committee before the end of February 2027. The list has no entry for GHK without copper (searched 21 November 2026). We do not infer one form’s status from the other’s.
Australia. The TGA says “many products promoted online are unapproved therapeutic goods and may be unlawful to import, supply or advertise. Using unapproved peptide products can pose serious health risks.” The Poisons Standard October 2026 names neither GHK nor GHK-Cu; it has group entries for copper compounds. We draw no scheduling conclusion of our own.
United Kingdom. The emc medicines database returned no results for GHK, copper tripeptide or prezatide (21 November 2026). It is not the full UK register.
Sport. Neither form is named on WADA’s 2026 or 2027 List. WADA says a peptide not specifically named “may still be prohibited”.
To see what a report for a given lot must show, read how to read a certificate of analysis.
05What we don’t know
Direct comparison
The two studies described here do not establish whether either form is preferable to the other.
Human evidence for GHK
The cited copper-free GHK paper is a cell and skin-equivalent study, not a participant study.
Product-level status
The status findings above do not settle the legal status of a specific product, or the status of copper-free GHK.
These limits are why the page does not name a winner. The two substances have different chemical identities, the studies use different models, and the status records answer narrow questions about specific lists and jurisdictions. None of those facts provides a basis for a general “better” verdict.
This is a plain-English summary of studies and public records checked on 21 November 2026. It is not legal or medical advice.